CN109620802A - 一种麻醉用鼻喷剂及其制备方法 - Google Patents
一种麻醉用鼻喷剂及其制备方法 Download PDFInfo
- Publication number
- CN109620802A CN109620802A CN201811482898.5A CN201811482898A CN109620802A CN 109620802 A CN109620802 A CN 109620802A CN 201811482898 A CN201811482898 A CN 201811482898A CN 109620802 A CN109620802 A CN 109620802A
- Authority
- CN
- China
- Prior art keywords
- injection
- nasal spray
- injector
- physiological saline
- anesthesia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开一种麻醉用鼻喷剂及其制备方法可用于成人门诊小手术克服局麻注射痛用，并可充分缓解术前术中紧张，配合度差，感受度差的问题；按重量组份计，麻醉用鼻喷剂它包括盐酸右美托咪定注射液3‑5ml；枸橼酸舒芬太尼注射液0.5‑2ml；生理盐水8‑10ml。麻醉用鼻喷剂制备方法，包括如下步骤a.用医用注射器A抽取盐酸右美托咪定注射液；b.用医用注射器B抽取枸橼酸舒芬太尼注射液；c.用医用注射器B抽取生理盐水将橼酸舒芬太尼注射液稀释；d.将医用注射器A和医用注射器B内的药液混合后静置3‑10分钟。
Description
技术领域
本发明涉及一种麻醉药品，尤其涉及一种麻醉用鼻喷剂及其制备方法。
背景技术
目前成人门诊小手术基本使用局部注射局麻药，患者术前术中紧张，术中局麻药注射痛，极易因为紧张，疼痛导致出血多，配合度差，感受度差，术后情绪抑郁的问题。局麻小手术给与全身麻醉存在适应症窄，患者术后不能即刻离院，容易出现恶心呕吐等问题。若单纯给与成人门诊小手术盐酸右美托咪定鼻喷剂又存在无镇痛，镇静效果微弱，难以达到患者满意度的问题。若单纯给与枸橼酸舒芬太尼注射液静脉注射又存在静脉扎针痛，呼吸抑制，必须专业麻醉医生实施的问题。
发明内容
本发明的目的在于克服现有技术的不足，适应现实需要，提供一种麻醉用鼻喷剂及其制备方法可用于成人门诊小手术克服局麻注射痛用，并可充分缓解术前术中紧张，配合度差，感受度差的问题。
为了实现本发明的目的，本发明所采用的技术方案为：
公开一种麻醉用鼻喷剂，按重量组份计，它包括：
盐酸右美托咪定注射液 3-5ml；
枸橼酸舒芬太尼注射液 0.5-2ml；
生理盐水 8-10ml。
一种麻醉用鼻喷剂，按重量组份计，它包括：
盐酸右美托咪定注射液 3-4ml；
枸橼酸舒芬太尼注射液 0.5-1ml；
生理盐水 8-9ml。
一种麻醉用鼻喷剂，按重量组份计，它包括：
盐酸右美托咪定注射液 4-5ml；
枸橼酸舒芬太尼注射液 1-2ml；
生理盐水 9-10ml。
一种麻醉用鼻喷剂，它包括：
盐酸右美托咪定注射液 4ml；
枸橼酸舒芬太尼注射液 1ml；
生理盐水 9ml。
所述盐酸右美托咪定注射液的浓度为 100μg/1ml。
所述枸橼酸舒芬太尼注射液的浓度为 50μg/1ml。
所述生理盐水为浓度为0.9％的生理盐水。
一种麻醉用鼻喷剂制备方法，包括如下步骤：
a.用医用注射器A抽取盐酸右美托咪定注射液；
b.用医用注射器B抽取枸橼酸舒芬太尼注射液；
c.用医用注射器B抽取生理盐水将橼酸舒芬太尼注射液稀释；
d.将医用注射器A和医用注射器B内的药液混合后静置3-10分钟。
步骤d中，静置5分钟。
步骤d中，静置8分钟。
本发明的有益效果在于：
本发明具有成本低，制备工艺简单，使用方法简单，无需特殊培训，对于成年人门诊小手术镇痛，镇静抗焦虑效果好，患者易于接受，副作用小，易于推广的优点，同时本发明的使用解决了单纯使用盐酸右美托咪定注射液用于鼻喷无镇痛，镇静效果微弱，难以达到患者满意度的问题，也解决了单纯使用枸橼酸舒芬太尼注射液鼻喷镇静效果差，小量镇痛差，大量存在呼吸抑制的问题。
具体实施方式
下面结合实施例对本发明进一步说明：
实施例1：一种麻醉用鼻喷剂。
按重量组份计，它包括：盐酸右美托咪定注射液4ml；枸橼酸舒芬太尼注射液2ml；生理盐水9ml。
本实施例中，所述盐酸右美托咪定注射液的浓度为110μg/1ml。所述枸橼酸舒芬太尼注射液的浓度为60μg/1ml，所述生理盐水为浓度为0.9％的生理盐水。
实施,2：一种麻醉用鼻喷剂。
按重量组份计，它包括：盐酸右美托咪定注射液3ml；枸橼酸舒芬太尼注射液0.5ml；生理盐水8ml。
本实施例中，所述盐酸右美托咪定注射液的浓度为90μg/1ml。所述枸橼酸舒芬太尼注射液的浓度为40μg/1ml。所述生理盐水为浓度为0.9％的生理盐水。
实施例3：一种麻醉用鼻喷剂。
按重量组份计，它包括：盐酸右美托咪定注射液4ml；枸橼酸舒芬太尼注射液1ml；生理盐水9ml。
本实施例中，所述盐酸右美托咪定注射液的浓度为100μg/1ml。所述枸橼酸舒芬太尼注射液的浓度为50μg/1ml。所述生理盐水为浓度为0.9％的生理盐水。
实施例4：一种麻醉用鼻喷剂。
按重量组份计，它包括：盐酸右美托咪定注射液5ml；枸橼酸舒芬太尼注射液1.5ml；生理盐水10ml。
本实施例中，所述盐酸右美托咪定注射液的浓度为90μg/1ml。所述枸橼酸舒芬太尼注射液的浓度为60μg/1ml。所述生理盐水为浓度为0.9％的生理盐水。
实施例5：一种麻醉用鼻喷剂制备方法，用于制备实施例1至实施例4任一所述的麻醉用鼻喷剂，包括如下步骤：
a.用医用注射器A抽取盐酸右美托咪定注射液；
b.用医用注射器B抽取枸橼酸舒芬太尼注射液；
c.用医用注射器B抽取生理盐水将橼酸舒芬太尼注射液稀释；
d.将医用注射器A和医用注射器B内的药液混合后静置3-10分钟后即可使用。
实施例6：与实施例5相同之处不再赘述，不同之处在于：步骤d中，静置5分钟。
实施例7：与实施例5相同之处不再赘述，不同之处在于：步骤d中，静置8分钟。
综上实施例1至实施例7，在本发明的麻醉用鼻喷剂使用中，使用时配置好的药液灌入耳鼻喉科专用鼻喷壶内，手术开始前15分钟经鼻孔每侧鼻腔喷一次，手术开始前5 分钟经鼻孔每侧鼻腔喷一次即可，本发明的麻醉用鼻喷剂中的盐酸右美托咪定注射液属于高选择型α2肾上腺素受体激动剂，具有镇静抗焦虑的作用，而枸橼酸舒芬太尼注射液主要作用于μ阿片受体，亲脂性更强，更易透过血脑屏障，两者混合使用可起到麻醉止疼、缓解焦虑紧张、感受度好的优点，对于成年人门诊小手术镇痛使用时，镇静抗焦虑效果好，患者易于接受，副作用小，易于推广，同时本发明的使用解决了单纯使用盐酸右美托咪定注射液用于鼻喷无镇痛，镇静效果微弱，难以达到患者满意度的问题，也解决了单纯使用枸橼酸舒芬太尼注射液鼻喷镇静效果差，小量镇痛差，大量存在呼吸抑制的问题。
本发明的实施例公布的是较佳的实施例，但并不局限于此，本领域的普通技术人员，极易根据上述实施例，领会本发明的精神，并做出不同的引申和变化，但只要不脱离本发明的精神，都在本发明的保护范围内。
Claims (9)
1.一种麻醉用鼻喷剂，其特征在于：按重量组份计，它包括：
盐酸右美托咪定注射液3-5ml；
枸橼酸舒芬太尼注射液0.5-2ml；
生理盐水8-10ml。
2.一种麻醉用鼻喷剂，其特征在于：按重量组份计，它包括：
盐酸右美托咪定注射液3-4ml；
枸橼酸舒芬太尼注射液0.5-1ml；
生理盐水8-9ml。
3.一种麻醉用鼻喷剂，其特征在于：按重量组份计，它包括：
盐酸右美托咪定注射液4-5ml；
枸橼酸舒芬太尼注射液1-2ml；
生理盐水9-10ml。
4.一种麻醉用鼻喷剂，其特征在于：按重量组份计，它包括：
盐酸右美托咪定注射液4ml；
枸橼酸舒芬太尼注射液1ml；
生理盐水9ml。
5.如权利要求1至4任一所述的麻醉用鼻喷剂，其特征在于：所述盐酸右美托咪定注射液的浓度为100μg/1ml。
6.如权利要求1至4任一所述的麻醉用鼻喷剂，其特征在于：所述枸橼酸舒芬太尼注射液的浓度为50μg/1ml。
7.如权利要求1至4任一所述的麻醉用鼻喷剂，其特征在于：所述生理盐水为浓度为0.9％的生理盐水。
8.一种麻醉用鼻喷剂制备方法，其特征在于：包括如下步骤：
a.用医用注射器A抽取盐酸右美托咪定注射液；
b.用医用注射器B抽取枸橼酸舒芬太尼注射液；
c.用医用注射器B抽取生理盐水将橼酸舒芬太尼注射液稀释；
d.将医用注射器A和医用注射器B内的药液混合后静置3-10分钟。
9.如权利要求8所述的麻醉用鼻喷剂制备方法，其特征在于：步骤d中，静置5分钟。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811482898.5A CN109620802A (zh) | 2018-12-05 | 2018-12-05 | 一种麻醉用鼻喷剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811482898.5A CN109620802A (zh) | 2018-12-05 | 2018-12-05 | 一种麻醉用鼻喷剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109620802A true CN109620802A (zh) | 2019-04-16 |
Family
ID=66071370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811482898.5A Pending CN109620802A (zh) | 2018-12-05 | 2018-12-05 | 一种麻醉用鼻喷剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109620802A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020259440A1 (zh) * | 2019-06-28 | 2020-12-30 | 四川普锐特药业有限公司 | 右美托咪定鼻喷剂、其制备方法及应用 |
| CN113975273A (zh) * | 2020-07-27 | 2022-01-28 | 宜昌人福药业有限责任公司 | 一种抗焦虑用纳米混悬鼻腔喷雾剂及其制备方法 |
| US11478422B2 (en) | 2018-06-27 | 2022-10-25 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| US11786508B2 (en) | 2016-12-31 | 2023-10-17 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| US11890272B2 (en) | 2019-07-19 | 2024-02-06 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104470516A (zh) * | 2011-12-11 | 2015-03-25 | 瑞克欧制药有限公司 | 鼻内右美托咪定组合物和其使用方法 |
| CN106727524A (zh) * | 2016-11-08 | 2017-05-31 | 叶茂 | 一种药物组合物及其应用 |
-
2018
- 2018-12-05 CN CN201811482898.5A patent/CN109620802A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104470516A (zh) * | 2011-12-11 | 2015-03-25 | 瑞克欧制药有限公司 | 鼻内右美托咪定组合物和其使用方法 |
| CN106727524A (zh) * | 2016-11-08 | 2017-05-31 | 叶茂 | 一种药物组合物及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| 杨又春等: ""枸橼酸舒芬太尼喷鼻用于术后镇痛的临床观察"", 《中国医药科学》 * |
| 王来虎等: ""右美托咪定与舒芬太尼用于全身麻醉术后镇痛的效果"", 《临床医学》 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11786508B2 (en) | 2016-12-31 | 2023-10-17 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| US11931340B2 (en) | 2016-12-31 | 2024-03-19 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| US11839604B2 (en) | 2016-12-31 | 2023-12-12 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| US11478422B2 (en) | 2018-06-27 | 2022-10-25 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| US11497711B2 (en) | 2018-06-27 | 2022-11-15 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| US11517524B2 (en) | 2018-06-27 | 2022-12-06 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| US11559484B2 (en) | 2018-06-27 | 2023-01-24 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| US11806429B2 (en) | 2018-06-27 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| WO2020259440A1 (zh) * | 2019-06-28 | 2020-12-30 | 四川普锐特药业有限公司 | 右美托咪定鼻喷剂、其制备方法及应用 |
| US11890272B2 (en) | 2019-07-19 | 2024-02-06 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| US11998529B2 (en) | 2019-07-19 | 2024-06-04 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| CN113975273B (zh) * | 2020-07-27 | 2023-07-11 | 宜昌人福药业有限责任公司 | 一种抗焦虑用纳米混悬鼻腔喷雾剂及其制备方法 |
| CN113975273A (zh) * | 2020-07-27 | 2022-01-28 | 宜昌人福药业有限责任公司 | 一种抗焦虑用纳米混悬鼻腔喷雾剂及其制备方法 |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| US11998528B1 (en) | 2023-01-12 | 2024-06-04 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109620802A (zh) | 一种麻醉用鼻喷剂及其制备方法 | |
| Warrington et al. | Use of intranasal medications in pediatric patients | |
| Bosmans et al. | Cardiovascular effects of epidural administration of methadone, ropivacaine 0.75% and their combination in isoflurane anaesthetized dogs | |
| Ko et al. | Evaluation of dexmedetomidine and ketamine in combination with various opioids as injectable anesthetic combinations for castration in cats | |
| Costa et al. | Effect of levobupivacaine, administered intraperitoneally, on physiological variables and on intrasurgery and postsurgery pain in dogs undergoing ovariohysterectomy | |
| Sacks et al. | Clinical comparison of dexmedetomidine and medetomidine for isoflurane balanced anaesthesia in horses | |
| Chari et al. | Comparison between intrathecal isobaric ropivacaine 0.75% with hyperbaric bupivacaine 0.5%: A double blind randomized controlled study | |
| Bigby et al. | The use of alfaxalone for premedication, induction and maintenance of anaesthesia in pigs: a pilot study | |
| WAGNER et al. | Hemodynamic function during neurectomy in halothaneanesthetized horses with or without constant dose detomidine infusion | |
| Krimins et al. | Evaluation of anesthetic, analgesic, and cardiorespiratory effects in dogs after intramuscular administration of dexmedetomidine–butorphanol–tiletamine-zolazepam or dexmedetomidine-tramadol-ketamine drug combinations | |
| Bertrand et al. | A combination of alfaxalone, medetomidine and midazolam for the chemical immobilization of Rhesus macaque (Macaca mulatta): Preliminary results | |
| Ueyama et al. | Effects of intravenous administration of perzinfotel, fentanyl, and a combination of both drugs on the minimum alveolar concentration of isoflurane in dogs | |
| de Vries et al. | Comparison of midazolam and diazepam as co-induction agents with ketamine for anaesthesia in sedated ponies undergoing field castration | |
| Calzetta et al. | A novel and effective balanced intravenous-inhalant anaesthetic protocol in swine by using unrestricted drugs | |
| CN101496801A (zh) | 右旋美托咪定及其药用盐的用途 | |
| Hashemi et al. | Ketamine–propofol for total intravenous anaesthesia in rabbits: a comparison of premedication with acepromazine–medetomidine, acepromazine–midazolam or acepromazine–morphine | |
| Greene et al. | Bispectral index in dogs anesthetized with isoflurane: comparison with sevoflurane | |
| Gautam et al. | A comparison on brachial plexus block using local anaesthetic agents with and without midazolam | |
| Auer et al. | A clinical study of the effects of rocuronium in isoflurane-anaesthetized cats | |
| Regmi et al. | Efficacy of tramadol as an adjuvant to bupivacaine for caudal analgesia in children: a randomised controlled trial | |
| Nastasi et al. | Peribulbar Sub-Tenon’s Anaesthesia With Levo-Bupivacaine and Cis-Atracurium Besilate in Ophthalmic Intraocular Surgery in Cat: Clinical Study. | |
| Sogebi et al. | Comparison of Two Neurolept-Analgesics Agents on Propofol-Isoflurane Anaesthesized Nigerian Indigenous Dogs. | |
| Kumar et al. | Comparative Clinical Study of 0.5% Hyperbaric Bupivacaine Alone and 0.5% Hyperbaric Bupivacaine with Midazolam Intrathecally for Lower Limb and Lower Abdominal Surgeries | |
| Zendeboudi et al. | Comparison of cardiopulmonary effects of propofol, ketamine-propofol and isoflurane anesthesia in the domestic chicken (Gallus gallus domesticus) | |
| Loomes et al. | Anaesthetic management of 10 horses undergoing cervical intervertebral body fusion ‘wobbler surgery’ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190416 |
|
| RJ01 | Rejection of invention patent application after publication |